Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer research hub

A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7)

This study is testing a new combination treatment for advanced ovarian, fallopian tube, or peritoneal cancers that haven't responded to previous chemotherapy. It compares a new drug, nemvaleukin alfa, with an existing cancer drug, pembrolizumab, against standard chemotherapy treatments to see if it helps people live longer.